Publication: Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications
Issued Date
2017-07-11
Resource Type
ISSN
22136711
Other identifier(s)
2-s2.0-85021993873
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Stem Cell Reports. Vol.9, No.1 (2017), 1-4
Suggested Citation
Peter W. Andrews, Uri Ben-David, Nissim Benvenisty, Peter Coffey, Kevin Eggan, Barbara B. Knowles, Andras Nagy, Martin Pera, Benjamin Reubinoff, Peter J. Rugg-Gunn, Glyn N. Stacey Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications. Stem Cell Reports. Vol.9, No.1 (2017), 1-4. doi:10.1016/j.stemcr.2017.05.029 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/41846
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Assessing the Safety of Human Pluripotent Stem Cells and Their Derivatives for Clinical Applications
Other Contributor(s)
University of Sheffield
Broad Institute
Hebrew University of Jerusalem
UCL Institute of Ophthalmology
University of California, Santa Barbara
Harvard University
Harvard Stem Cell Institute
Jackson Laboratory
Mahidol University
Mount Sinai Hospital of University of Toronto
Monash University
University of Melbourne
The Florey Institute of Neuroscience and Mental Health
Walter and Eliza Hall Institute of Medical Research
Hadassah University Medical Centre
The Babraham Institute
Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute
Medicines and Health Care products Regulatory Agency
Broad Institute
Hebrew University of Jerusalem
UCL Institute of Ophthalmology
University of California, Santa Barbara
Harvard University
Harvard Stem Cell Institute
Jackson Laboratory
Mahidol University
Mount Sinai Hospital of University of Toronto
Monash University
University of Melbourne
The Florey Institute of Neuroscience and Mental Health
Walter and Eliza Hall Institute of Medical Research
Hadassah University Medical Centre
The Babraham Institute
Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute
Medicines and Health Care products Regulatory Agency
Abstract
© 2017 Pluripotent stem cells may acquire genetic and epigenetic variants during culture following their derivation. At a conference organized by the International Stem Cell Initiative, and held at The Jackson Laboratory, Bar Harbor, Maine, October 2016, participants discussed how the appearance of such variants can be monitored and minimized and, crucially, how their significance for the safety of therapeutic applications of these cells can be assessed. A strong recommendation from the meeting was that an international advisory group should be set up to review the genetic and epigenetic changes observed in human pluripotent stem cell lines and establish a framework for evaluating the risks that they may pose for clinical use.